grant

Genetic and Proteomic Approaches to Reveal Bacterial Vulnerabilities to Phage Predation

Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 20 May 2022Deadline 30 Apr 2027
NIHUS FederalResearch GrantFY2026AddressAffinityAffinity ChromatographyAnti-Bacterial AgentsAntibiotic AgentsAntibiotic DrugsAntibiotic ResistanceAntibioticsAssayAutomobile DrivingBacteriaBacteria resistanceBacteria resistantBacterial InfectionsBacterial PhysiologyBacterial resistantBacteriophagesBindingBioassayBiochemicalBioinformaticsBiological AssayBiologyCRISPRCRISPR/Cas systemCatalogingCell BodyCell DeathCell FractionationCellsClustered Regularly Interspaced Short Palindromic RepeatsComplementComplement ProteinsComplexCoupledCytolysisDataData AnalysesData AnalysisDetectionEngineeringEnsureEssential GenesFamilyFortificationFutureGene TranscriptionGeneralized GrowthGenesGeneticGenetic TranscriptionGoalsGrowthHost FactorHost Factor ProteinHumanImmune systemInfectionIntegration Host FactorsInvestigatorsLibrariesLysisLyticMDR P aeruginosaMDR P. aeruginosaMDR Pseudomonas aeruginosaMapsMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMethodsMiscellaneous AntibioticModelingModern ManMolecular InteractionNGS MethodNGS systemOutcomeP aeruginosaP. aeruginosaPathogenesisPathway interactionsPhagesPredatory BehaviorPredispositionProcessProteinsProteomeProteomicsPseudomonas aeruginosaPseudomonas aeruginosa multi drug resistancePseudomonas pyocyaneaRNA ExpressionReagentRepressionResearchResearch PersonnelResearchersResistanceResistance to antibioticsResistant to antibioticsRoleSeriesSurvey InstrumentSurveysSusceptibilitySystemTherapeuticTimeTissue GrowthTranscriptionValidationViral DiseasesVirus Diseasesaffinity purificationanti-bacterialantibiotic drug resistanceantibiotic resistantbacteria infectionbacterial diseasebacterial fitnessbacterial geneticsbacterial resistancebacterial virusbiophysical characteristicsbiophysical characterizationbiophysical measurementbiophysical parametersbiophysical propertiescombatcomplementationdata interpretationdesigndesigningdiscover genesdrivingeffective therapyeffective treatmentfightinggene discoverygene interactionhuman pathogenin vivoinhibitorknock-downknockdownmulti-drug resistant P. aeruginosamulti-drug resistant Pseudomonas aeruginosamultidrug resistant P. aeruginosamultidrug-resistant P. aeruginosamultidrug-resistant Pseudomonas aeruginosanecrocytosisnext gen sequencingnext generation sequencingnextgen sequencingnovelontogenypathogenpathwaypredationprotein complexprotein protein interactionresistance generesistance locusresistance mechanismresistance to Bacteriaresistance to Bacterialresistantresistant generesistant mechanismresistant to Bacteriaresistant to Bacterialresponsescreeningscreeningsskillssmall moleculesocial rolesubcellular fractionationsuccesstoolvalidationsviral infectionvirus infectionvirus-induced disease
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY
We are entering a post antibiotic world where understanding the mechanism of an antibacterial strategy is not

sufficient to ensure an effective therapy. We must also consider the mechanisms of resistance and address them

during the design process. We will use genetics and proteomics to discover how bacteria combat bacteriophage

(phage) lysis. Driving this goal is the desire to combat phage resistance mechanisms so as to make bacteria

more susceptible to phage predation. We first tackle the problem by employing state of the art genetic methods

to interrogate the role of essential genes in limiting phage replication and bacterial lysis. Using CRISPR

transcriptional interference (CRISPRi), we will conduct the first studies in the human pathogen Pseudomonas

aeruginosa to determine whether partial knockdown of essential genes can positively impact phage replication.

We hypothesize that inhibition of certain essential genes will not only limit bacterial fitness, but also has the

potential to enhance the success of any phage-host pairing, regardless of whether the a priori state is one of

phage resistance or sensitivity. Put another way, even phages that already replicate in a given host can do better.

We will additionally harness the ease of CRISPRi screening to identify non-essential genes that limit phage

replication in strain-dependent manners, more akin to canonical hypervariable immune systems (e.g. CRISPR).

To further our understanding of the physical underpinnings of phage resistance, we will create a physical map

of phage-host protein-protein interactions using whole cell fractionation proteomics. This is particularly critical as

many phage proteins are of unknown function and is in line with our goal of identifying essential protein

complexes interacting with phage factors. We will validate the importance of factors identified from genetic and

proteomic assays with phage replication assays during single gene knockdown to assess generalities of

phenomena observed. Lastly, we suspect that phage “accessory genes” (i.e. hypervariable loci not strictly

essential for phage replication in all hosts) represent a treasure trove of inhibitors and modulators of host

processes, which could be useful genetic fodder for enhancing future phage therapeutics. Accessory genes have

been bioinformatically identified and host binding partners will be identified with conventional affinity purification-

mass spectrometry, and validated with phage replication assays. Our research strategy combines the

complementary expertise of three investigators: Joseph Bondy-Denomy, an expert in phage biology and bacterial

immune systems; and Danielle Swaney, an expert in bioanalytical mass spectrometry who has used her skills to

define the host-pathogen protein-protein network for many human pathogens; and Jason Peters, a microbiologist

with expertise in bacterial genetics and pathogenesis.

Grant Number: 5R01AI167412-05
NIH Institute/Center: NIH

Principal Investigator: Joseph Bondy-Denomy

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →